STELAZINE Spansules Capsules (Hard Gelatin)
Trifluoperazine
15mg
SmithKline & French Labs. Ltd.
| Pack size | 100's Bottle |
|---|---|
| Dispensing mode | POM |
| Source | UK |
| Agent | GULF DRUG EST. |
| Retail Price | 115.50 AED |
Available as:
Indications
STELAZINE Spansules Capsules (Hard Gelatin) is used for:
Anxiety, Psychoses, Nausea and vomiting, Schizophrenia
Adult Dose
Oral
Psychoses, Schizophrenia
Adult:
Outpatient
1-2 mg PO q12hr
Inpatient
Initial: 2-5 mg PO q12hr
Maintenance Dose: 15-20 mg/day
Not to exceed 40mg/day
Short-term management of anxiety
Adult: 1-2 mg bid. Max: 6 mg daily. Max duration: 12 wk.
Elderly: Initiate at lower dose and increase gradually.
Child Dose
Schizophrenia/Psychosis
Inpatient
<6 years: Safety and efficacy not established
6-12 years old: 1 mg PO qDay or q12hr; not to exceed 15 mg/day
12 years old: 2-5 mg PO q12hr
Renal Dose
Administration
Should be taken with food.
Contra Indications
Preexisting CNS depression and coma; bone marrow depression, blood dyscrasias, liver disease, hypersensitivity to phenothiazines, prolactin dependent tumours. Pregnancy (1st trimester), lactation.
Precautions
Cardiovascular disease, epilepsy, angle-closure glaucoma, exposure to extreme temperatures, elderly, parkinson's disease, myasthenia gravis, benign prostatic hyperplasia, DM, renal amd hepatic impairment. Discontinue trifluoperazine at least 48 hr before myelography and do not resume for at least 24 hr after procedure. Do not use trifluoperazine in control of nausea and vomiting occurring either prior to myelography or postprocedure with metrizamide. Pregnancy.
Pregnancy-Lactation
Pregnancy Category: C
Neonates exposed to antipsychotic drugs during the 3rd trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms following delivery
These complications vary in severity; in some cases, symptoms have been self-limited, while in other cases neonates have required intensive care unit support and prolonged hospitalization
Lactation: unknown
Interactions
Increased CNS depression with CNS depressants such as opiates or other analgesics, barbiturates or other sedatives, general anaesthetics, or alcohol. Increased risk of side effects with drugs with antimuscarinic properties e.g. TCA, antiparkinsonian drugs. Antagonised effects of dopaminergic drugs such as levodopa. Increased risk of hypotension with antihypertensives, trazodone. Reverses antihypertensive effect of guanethidine. Increased risk of severe extrapyramidal side-effects or severe neurotoxicity with lithium. Possible decrease in absorption with antacids.
Adverse Effects
Side effects of Trifluoperazine :
EPS (60%; muscle stiffness, dystonia, parkinsonism, tardive dyskinesia, akathisia), Drowsiness, dry mouth, blurred vision, dizziness, sedation, antimuscarinic affects, postural hypotension, akathisia, muscle weakness, anorexia, insomnia, rash, amenorrhoea, fatigue, increased prolactin levels.
Potentially Fatal: Neuroleptic malignant syndrome, blood dyscrasias.
Mechanism of Action
Trifluoperazine inhibits dopamine D2 receptors in the brain. It has weak anticholinergic and sedative effects but strong extrapyramidal and antiemetic effects. It controls severely disturbed, agitated or violent behaviour but may also be used for nonpsychotic anxiety.
Note
STELAZINE Spansules 15mg Capsules (Hard Gelatin) manufactured by SmithKline & French Labs. Ltd.. Its generic name is Trifluoperazine. STELAZINE Spansules is availble in United Arab Emirates.
Farmaco UAE drug index information on STELAZINE Spansules Capsules (Hard Gelatin) is not intended for diagnosis, medical advice or treatment; neither intended to be a substitute for the exercise of professional judgment.